Interleukin 24 gene therapy + radiotherapy in patients with locally advanced, unresectable, head and neck cancer.
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2014
Price : $35 *
At a glance
- Drugs Interleukin 24 gene therapy-MultiVir (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors MultiVir
- 03 Mar 2014 New trial record
- 14 Feb 2014 Top-line results presented at the Leerink Global Healthcare conference reported in a MultiVir media release.